Pfizer Inc. Receives EU Marketing Authorization for INLYTA®(Axitinib)

Published: Sep 04, 2012

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA® (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine. INLYTA, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit vascular endothelial growth factor (VEGF) receptors 1, 2 and 3,1a which are proteins that can influence tumor growth, vascular angiogenesis and progression of cancer (tumor spread).2a

Back to news